Impact of a 6-month treatment with intragastric balloon on body composition and psychopathological profile in obese individuals with metabolic syndrome
Authors:
- Erika P. GuedesEGErika P. Guedes
- Eduardo MadeiraEMEduardo Madeira
- Thiago T. MafortTMThiago T. Mafort
- Miguel MadeiraMMMiguel Madeira
- Rodrigo O. MoreiraRMRodrigo O. Moreira
- Laura Maria C. MendonçaLMLaura Maria C. Mendonça
- Amélio F. Godoy-MatosAGAmélio F. Godoy-Matos
- Agnaldo J. LopesAgnaldo J. Lopes
- Maria Lucia F. FariasMFMaria Lucia F. Farias
Open Access
- 19 December 2016
- journal article
- research article
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 8 (1) , 1-7
Abstract
Background: The aim of this study was to investigate the effects of a 6-month treatment with intragastric balloon (IGB) on body composition and depressive/anxiety symptoms in obese individuals with metabolic syndrome (MS). Methods: Fifty patients (aged 18–50 years) with obesity and MS were selected for treatment with IGB for 6 months. Body composition was verified with dual-energy X-ray absorptiometry (DXA) at baseline and right after IGB removal. Anxiety/depressive symptoms were assessed with the Beck Depression Inventory (BDI) and the hospital anxiety and depression scale (HADS) at baseline and after 6 months of treatment. Results: In total, 39 patients completed the study. After 6 months, there were significant decreases in weight (11.7 ± 9.6 kg, p < 0.0001) and waist circumference (9.3 ± 8.2 cm, p < 0.0001). Weight loss was also demonstrated by DXA and corresponded to decreases of 3.0 ± 3.4% in body fat percentage, 7.53 ± 7.62 kg in total body fat, and 3.70 ± 4.89 kg in lean body mass (p < 0.001 for all comparisons). Depressive symptoms scores decreased by a mean of 4.57 ± 10.6 points when assessed with the BDI (p = 0.002) and 1.82 ± 5.16 points when assessed with the HADS-Depression (p = 0.0345). Anxiety symptoms scores decreased by a mean of 1.84 ± 4.04 points when determined with the HADS-anxiety (p = 0.0066). The decrease in body fat percentage was the parameter that best correlated with improvements in depressive (p = 0.008) and anxiety symptoms (p = 0.014). Conclusions: In obese individuals with MS, fat mass reduction was associated with short-term improvements in depressive and anxiety symptoms. Trial Registration Registered at ClinicalTrials.gov, NCT01598233Keywords
Funding Information
- Silimed Silicone Instrumental Médico Cirúrgico Hospitalar Ltda, Rio de Janeiro, RJ, Brazil.
This publication has 49 references indexed in Scilit:
- Effects of the Intragastric Balloon MedSil® on Weight Loss, Fat Tissue, Lipid Metabolism, and Hormones Involved in Energy BalanceObesity Surgery, 2014
- Body composition and depressive/anxiety symptoms in overweight and obese individuals with metabolic syndromeDiabetology & Metabolic Syndrome, 2013
- Liver steatosis (LS) evaluated through chemical-shift magnetic resonance imaging liver enzymes in morbid obesity; effect of weight loss obtained with intragastric balloon gastric bandingActa Diabetologica, 2013
- A systematic review of variables associated with the relationship between obesity and depressionObesity Reviews, 2013
- Body mass index and common mental disorders: exploring the shape of the association and its moderation by age, gender and educationInternational Journal of Obesity, 2011
- Obesity and depression symptoms in the Beaver Dam Offspring Study populationDepression and Anxiety, 2010
- Impact of body mass index on the psychopathological profile of obese womenBrazilian Journal of Psychiatry, 2010
- Effects of sibutramine and orlistat on mood in obese and overweight subjects: A randomised studyNutrition, Metabolism and Cardiovascular Diseases, 2008
- Body composition modification in obese patients treated with intragastric balloonActa Diabetologica, 2003
- Anxiety, depression, hunger and body composition: III. Their relationships in obese patients.Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, 1999